Introduction to India’s Role in Multi-Regional Clinical Trials (MRCTs) and Global Clinical Development
As multi-regional clinical trials (MRCTs) continue to shape modern drug development, sponsors must design studies that are globally relevant, operationally efficient, and regulatorily robust. In this evolving landscape, India has emerged as a key contributor in global clinical trials and MRCT strategies. Its growing role reflects advancements in clinical research in India, strong investigator networks, and improving regulatory processes.India’s role is like a strategic component, that must be thoughtfully integrated into a broader global trial design.
Global regulators such as the U.S. Food and Drug Administration and the European Medicines Agency expect MRCTs to generate data that is representative across populations. As outlined in ICH E17, maintaining regional balance is essential for ensuring global acceptability.
In this context, India contributes significantly to recruitment, diversity, and cost efficiency, but must be strategically integrated alongside major regions such as the United States, Europe, and Asia to maintain balance in multi-regional clinical trials (MRCTs).
Why India Matters in Multi-Regional Clinical Trials (MRCTs)
India’s importance in clinical trials in India and MRCT strategies is driven by its large and diverse patient population, experienced investigators, and evolving regulatory framework. These factors make India a valuable geography in global clinical development programs that attribute in accelerating clinical development timelines.
However, India’s role is most effective when positioned as part of a broader global strategy rather than as a standalone solution.
India as an Enrollment Engine in Global Clinical Trials
One of the strongest advantages of India in global clinical trials is its ability to accelerate patient recruitment. High disease burden and access to diverse patient populations make India an efficient recruitment hub.
Many clinical trials companies in India and global sponsors rely on India to meet enrollment targets faster. However, maintaining balance is critical, as over-representation from a single region may impact regulatory acceptance.
Enhancing Population Diversity in MRCTs
India plays a key role in improving diversity within multi-regional clinical trials (MRCTs) by introducing South Asian populations into global datasets.This diversity strengthens the overall dataset by improving the generalizability of results across global populations. It also supports a more comprehensive benefit–risk assessment, which is a key requirement for regulatory approvals
However, India should complement, not replace, diversity from other global regions.MRCTs must include multiple regions to capture variability across ethnic groups
Cost Efficiency of Clinical Trials in India
India offers a cost-effective environment for conducting clinical trials. Compared to Western regions, clinical trial recruitment in India and site operations are significantly more economical.
This cost advantage allows sponsors to optimize budgets while maintaining high-quality data standards. Still, cost efficiency must be balanced with regulatory and operational considerations.
However, cost efficiency should not be the sole driver of country selection. Decisions must also consider data quality, regulatory acceptance, and operational feasibility. A purely cost-driven approach can lead to suboptimal outcomes if it compromises other critical factors.
India’s Role in Global Regulatory Strategy
India contributes meaningfully to global submissions by enhancing data diversity. However, major regulatory decisions are typically driven by data from regions such as the US and Europe.
India’s contribution strengthens the dataset but works best as part of a globally balanced MRCT design.
Data from India is included as part of the overall evidence package. CLINEXEL CSO, Dr Mukesh Kumar states, that while Indian clinical data contributes meaningfully to global submissions by enhancing diversity and real-world relevance, but is rarely the sole basis for approval decisions in major markets. This does not diminish its importance; rather, it highlights the need for balanced representation across regions.[DA1]
Sponsors must ensure that the inclusion of India complements data from other regions, contributing to a cohesive and globally acceptable dataset.
India in Consistency Evaluation (ICH E17 Perspective)
In line with ICH E17, India’s data plays a role in evaluating treatment consistency across populations. Subgroup analyses often include Indian patient data to ensure results are globally applicable.
This reinforces India’s importance in scientific validation within MRCTs.
Dr. Kumar further adds, Indian patient data is typically included in pre-specified regional or subgroup analyses to assess whether treatment effects are consistent with those observed in other regions. The goal is to demonstrate that there are no clinically meaningful differences that would impact the overall interpretation of results.
This makes India an important contributor to the scientific robustness of MRCTs, beyond its role in recruitment.
Operational Strength of CROs in India
India’s growing ecosystem of CROs in India and Contract Research Organizations in India enables efficient trial execution. Organizations like CLINEXEL operating within the AICROS network, provide expertise in regulatory navigation, site management, and patient recruitment.
The presence of experienced pharmaceutical CRO India services enhances operational efficiency and supports global trial execution.
CLINEXEL CEO Dr Deepa mentions“India has a large network of clinical trial sites, many of which have extensive experience in global studies. Investigators are increasingly familiar with international protocols and Good Clinical Practice standards.”She further states “In global clinical, India’s operational capabilities enable rapid study start-up and scalability, making it an attractive option for multi-site enrollment strategies.”
Challenges of Including India in MRCTs
Despite its advantages, including India in MRCTs requires careful planning and management of certain limitations.. Variability in standard of care, regulatory perceptions, and data consistency must be managed effectively.
Medical practices in India may differ from those in the United States or Europe, which can affect endpoint assessments and overall data consistency.
Data variability is another consideration. Differences in diagnostic approaches, patient management, and reporting practices can introduce variability that must be accounted for in study design and analysis.
Regulatory perception is also important. If a disproportionate number of patients are enrolled from India, regulators may scrutinize the data more closely to ensure that results are generalizable to other populations.
These challenges do not preclude the inclusion of India but underscore the importance of thoughtful planning and high-quality execution.
Proper site selection and protocol alignment are essential to mitigate these risks.
Best Practices for Including India in MRCTs
To maximize the benefits of India in MRCTs, sponsors should:
- Maintain balanced regional representation
- Use India to accelerate recruitment
- Partner with experienced CROs in India
- Ensure alignment with global regulatory expectations
- Focus on high-quality site selection
India’s Strategic Position in MRCT Design
India is typically positioned as a high-enrollment region that supports global clinical trials. Its contribution improves efficiency, enhances diversity, and strengthens overall study outcomes.
India is rarely the anchor region for regulatory submissions but plays a vital supporting role in strengthening the overall evidence package. Its inclusion allows sponsors to optimize timelines, improve efficiency, and enhance the global relevance of their studies.
Conclusion: India as a Strategic Lever in MRCTs
India has become a critical component of multi-regional clinical trials (MRCTs), offering advantages in recruitment, cost efficiency, and operational scalability. However, its success depends on strategic integration within a global trial framework.
A balanced approach that combines India’s strengths with contributions from other key regions ensures that clinical data is robust, diverse, and regulatorily acceptable.
By aligning with global frameworks such as the ICH E17 and leveraging clinical research in India, with local expertise through organizations like CLINEXEL and AICROS, sponsors can design MRCTs that are both efficient and scientifically sound.
In today’s competitive clinical development environment, India is not just a location, it is a strategic lever that drives efficiency, diversity, and global impact.These when used correctly, can significantly accelerate clinical development and improve global patient access to innovative therapies.
Frequently Asked Questions (FAQs)
Why is India included in multi-regional clinical trials (MRCTs)?
India is included in multi-regional clinical trials (MRCTs) to accelerate patient recruitment, reduce clinical trial costs, and enhance population diversity in global clinical research.
Is India sufficient as a standalone region in MRCTs?
No, India is not sufficient as a standalone region in MRCTs. It must be combined with other regions such as the United States and Europe to ensure global regulatory acceptance and balanced clinical data.
What are the risks of including India in MRCTs?
Key risks of including India in MRCTs include variability in standard of care, potential data variability, and increased regulatory scrutiny if patient representation from India is disproportionately high.
How does India contribute to regulatory submissions in clinical trials?
India contributes to regulatory submissions by providing supporting clinical data that strengthens the overall evidence package, although it is typically not the primary basis for regulatory approvals.
Which guideline governs multi-regional clinical trial (MRCT) design?
The ICH E17 guideline provides the global framework for designing multi-regional clinical trials (MRCTs), ensuring consistency, data quality, and regulatory alignment across regions.
Authors:
Dr. Deepa Arora- CEO- CLINEXEL (https://www.linkedin.com/in/deepaarora2019/)
Dr Deepa is a physician with 25+ years of industry experience in leadership positions with pharma in Clinical Development, Medical Research, and Drug Safety departments.
Dr. Deepa led an industry consortium for the implementation of additional risk minimization measures in Europe. Her experience includes the development and execution of clinical development strategy and conducting clinical trials for NCEs, biosimilars, vaccines, complex generics, and repurposed drugs.
Deepa has experience in interacting with various regulators- USFDA, EMA, MHRA, MEB, Health Canada, WHO, TGA for scientific advice, pre-IND meetings, end of phase meetings to discuss clinical development path, clinical trial designs, and post-marketing commitments, including PMS/ Phase IV studies and paediatric investigation plan (PIP).
Dr. Mukesh Kumar– Chief Scientific Officer- CLINEXEL (https://www.linkedin.com/in/dr-mukesh-kumar-m-d-6223457/)
A Physician (MD) with over 25 years of deep expertise in clinical R&D, Dr Kumar’s career is a testament to innovation and excellence in clinical trials, clinical pharmacology, translational research, biopharmaceutics, and clinical development. His contributions have driven global product registrations across regulatory landscapes, including the USFDA, EMA, India, PMDA, and ROW regions.
Dr. Kumar’s illustrious career includes clinical R&D leadership roles at global pharmaceutical giants (Sanofi and Daiichi Sankyo) and large Indian pharma companies (CIPLA, DRL, and LUPIN), where he supported early and late phase clinical trials of innovative products, including repurposed drugs via 505(b)(2) path, complex generics, and biosimilars. He has played a key role in transforming the R&D business through clinical risk mitigation strategies and high-quality clinical trial executions. With a proven track record of significant contributions in clinical development of over 100 successful product registrations in the U.S. and Europe, he has redefined efficiencies in clinical strategies by implementing cost-effective, innovative clinical trials and pharmacology studies.
As CLINEXEL’s CSO, Dr. Kumar oversees clinical trial operations (Phases I-IV) and clinical program management. His value-added support is available for CLINEXEL-managed clinical trials in optimizing clinical strategies, global clinical development, and driving impactful scientific negotiations for innovative therapies, biosimilars, and complex generics.